Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
OSE Immunotherapeutics
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
May 31, 2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
May 26, 2026
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
May 26, 2026
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
May 25, 2026
OSE Immunotherapeutics Evolves its Leadership Team
May 24, 2026
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
May 17, 2026
OSE Immunotherapeutics salue l’octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)
January 21, 2026